Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs
About This Grant
Doxorubicin is a highly effective chemotherapeutic agent used for treating a wide range of malignancies, including breast cancer and pediatric cancers. However, its clinical utility is often limited by life-threatening cardiotoxicity, which can lead to irreversible heart failure. While clinical risk factors such as cumulative dose and age are well-established, individual genetic susceptibility plays a critical role in doxorubicin-induced cardiotoxicity (DIC). Currently, predicting which patients will develop DIC remains challenging. The longterm goal of this project is to identify genetic determinants of DIC to enable precise risk stratification and cardioprotection. During the K99 phase, the Principal Investigator (Pl) successfully established a highthroughput CRISPR interference/activation (CRISPRi/a) screening platform in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). In the R00 independent phase, the Pl will transition from gene-level perturbation to the characterization of specific genetic variants or single nucleotide polymorphisms (SNPs). Specifically, Aim 3 (R00 Phase) will utilize Prime Editing 7 (PE?), a precise genome editing technology, to install a library of 116 clinically implicated genetic variants into human iPSCCMs. This "in vitro GWAS" approach will quantify the functional impact of each variant on cardiomyocyte survival under doxorubicin stress. Top candidate variants will be further validated using high-throughput 3D engineered heart tissues (EHTs) to assess physiological contractility and automated live-cell imaging to determine cytotoxicity kinetics. Finally, these functional biological scores will be integrated with clinical GWAS data to generate Integrated Risk Scores. This research will bridge the gap between clinical genetics and functional biology, establishing a foundation for the personalized prediction and prevention of chemotherapy-induced heart failure.
Grant Summary
Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs is a NHLBI - National Heart Lung and Blood Institute grant providing up to $249K for university, nonprofit, healthcare org. Applications are due 2029-04-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $249K
2029-04-30
- 1Confirm your organization is eligible for Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs from NHLBI - National Heart Lung and Blood Institute, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NHLBI - National Heart Lung and Blood Institute before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NHLBI - National Heart Lung and Blood Institute's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs: Frequently Asked Questions
Who is eligible for the Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs?
Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs is offered by NHLBI - National Heart Lung and Blood Institute and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs provide?
Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs provides up to $249K per award from NHLBI - National Heart Lung and Blood Institute. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs deadline?
Applications for Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs are due 2029-04-30 (open). Because deadlines can change, verify the date with the funder, NHLBI - National Heart Lung and Blood Institute, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs?
To apply for Parallel Characterization of Genetic Variants in Chemotherapy-Induced Cardiotoxicity Using iPSCs, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NHLBI - National Heart Lung and Blood Institute.